HepaGam B - cure for hepatitis B

FDA has approved the HepaGam B, a drug that was seeking approval from FDA for the prevention of hepatitis B reinfection that takes place in case of some specific liver transplant patients.

HepaGam B, an immune globulin product, has got the approval from FDA finally and will now be used to cure patients that get the reinfaction of hepatitis B in case of liver transplant patients.

HepaGam B when used, provides an immediate immune response to the hepatitis b virus. This immunity that is provided by Hepagam B protects the patient that has been previously exposed to Hepatitis B virus.